Name (Synonyms) | Correlation | |
---|---|---|
drug2493 | The standard Macintosh laryngoscope Wiki | 0.41 |
drug2488 | The Vie Scope laryngoscope Wiki | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
D004066 | Digestive System Diseases NIH | 0.24 |
D005767 | Gastrointestinal Diseases NIH | 0.24 |
D008103 | Liver Cirrhosis, NIH | 0.20 |
D012120 | Respiration Disorders NIH | 0.12 |
D012140 | Respiratory Tract Diseases NIH | 0.10 |
D018352 | Coronavirus Infections NIH | 0.03 |
D007239 | Infection NIH | 0.02 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001395 | Hepatic fibrosis HPO | 0.20 |
HP:0011024 | Abnormality of the gastrointestinal tract HPO | 0.17 |
There are 6 clinical trials
To address the existing deficiencies in the knowledge regarding liver involvement and spectrum of clinical presentation and the impact of COVID-19 infection in patients of liver disease was planned. The present study will be a hospital based and the cases of confirmed COVID-19 infection will be evaluated in relation to liver involvement irrespective of pre-existing liver disease. The primary objective was to address the clinical presentation, biochemical alteration and outcomes of COVID-19 infection in subjects with chronic hepatitis, cirrhosis in comparison to those having infection in the absence of pre-existing liver disease
COVID19 pandemic currently represents a public health emergency. Based on current data, 15% of the affected individuals will develop a severe form of the disease requiring admission to hospital and respiratory support. Data show that age and cardiovascular pre-existing comorbidities predict a poorer outcome. Some evidence suggests that a subset of patients with poorer outcome present with a cytokine mediated inflammatory response and with a secondary HLH like clinical phenotype. No data are so far available with regard to the risk of severe COVID19 disease in the post stem cell transplantation setting. Recipients of allogeneic stem cell transplantation are by definition immunologically dysregulated and could potentially present with a unique immune-inflammatory response to COVID 19 infection. Moreover, the immunosuppression used to prevent/treat GVHD may also impact clinical progression and it is possible that because of their immunological defects, SCT patients could potentially have prolonged carriage of the virus and hence act as "super spreaders". The present study aims at documenting clinical and biological characteristics, including immunological profiling, of allogeneic stem cell transplant recipients presenting with severe COVID 19 infection and its impact on patients survival. This work may provide the scientific basis for targeted therapy with biological agents in this patient group.
This is a multi-centered, retrospective, observational study aimed at observing the current status of the management of gastrointestinal surgery during the COVID-19 pandemic, particularly the changes on surgery protocols and other key aspects of surgical workflow, so as to share experience with colleagues both domestic and abroad.
Description: proportion of patients presented with fever, proportion of patients refered to fever clinics, proportion of patients screened for COVID-19, method of screening (CT? nucleated acid test?)
Measure: treatment of fevers at arrival Time: 1 dayDescription: proportion of patients on whom fever occured, proportion of patients screened for COVID-19, method of screening (CT? nucleated acid test?)
Measure: treatment of post-operative fevers Time: 1 dayDescription: Duration of operation (≥180min/<180min); Intra-operative transfusion (Y/N); Surgical approach (Laparoscopy-involved/Open); Resection range (Non-radical/Radical); Lymph node dissection (Unknown/Not dissected/D1/D2 or above); Combined organ resection (Y/N); Post-operative complications (Y/N); Post-operative transfusion (Y/N); Post-operative hospital stay (≥7d/<7d)
Measure: assorted surgical parameters Time: 1 dayDescription: Out-patient of surgery (Open/Closed); Emergency of surgery (Open/Closed); Fever clinic (Open/Closed); Surgical ward (Open/Closed); Functional level of surgical ward (Receive emergency surgery patients only/Receive surgery patients only/Receive all kinds of patients); Isolation ward for suspected COVID-19 patients (With/Without); Bed number in each surgical ward room (1/2/≥3); Isolation area within surgical ward (With/Without); Usage of sub-pressure operation theaters (Routinely applied/Applied for suspected patients/Never applied); Protection level of surgeons in surgical ward (No specific protection/Regular medical masks/Any of N95 mask, eye/face shields, gowns); Protection level of surgeons in ER room (No specific protection/Regular medical masks/Any of N95 mask, eye shields, face shields, gowns)
Measure: hospitals' protection measures and extent of implementation Time: 1 monthTo investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. The investigators wish figure out the clinical character of the fatal participants. The result may help the physician to find the fatal patients with COVID-19 more easily. The fatal patients with COVID-19 could be treated early.
Description: the counting of Lymphocyte(counts/L)
Measure: Lymphocyte cell Time: 2 monthDescription: d-dimer(mg/L)
Measure: d-dimer Time: 2 monthDescription: the counting of Platelets((counts/L))
Measure: PLT Time: 2 monthDescription: the level of C-reactive protein (mg/uL)
Measure: CRP Time: 2 monthDescription: lactate dehydrogenase ( U/L)
Measure: LDH Time: 2 monthDescription: creatine kinase (U/L)
Measure: CK Time: 2 monthDescription: prothrombin time(second)
Measure: PT Time: 2 monthDescription: alanine aminotransferase(U/L)
Measure: ALT Time: 2 monthDescription: aspartate aminotransferase(U/L)
Measure: AST Time: 2 monthDescription: natural killer cell(counts/L)
Measure: NK cell Time: 2 monthDescription: procalcitonin(ng/ml)
Measure: PCT Time: 2 monthDescription: interleukin-6(mg/L)
Measure: IL-6 Time: 2 monthDescription: CT scan feature
Measure: the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases Time: 2 monthsDescription: oxygen Saturation
Measure: SPO2 Time: 2 monthA new Coronavirus (SARS-CoV-2) emerged in Wuhan Province, China in December 2019 and rapidly spread around the world. To date, the data in the literature regarding the clinical and epidemiological characteristics of severe forms of CoVid-19 in patients with chronic respiratory disease are not well known. The hypothesis is that patients with chronic respiratory disease (COPD, asthma, bronchial dilatations, pulmonary hypertension, cystic fibrosis, obesity-hypoventilation syndrome, obstructive sleep apnea syndrome) infected with SARS-Cov-2 will have increased dyspnea and hypoxemia leading to hospitalization for severe forms more frequently than the general population. However, they do not appear to be more at risk of developing a critical form. This study is carried out in order to propose to estimate the prevalence of critical forms of CoVid19 among patients with chronic respiratory diseases hospitalized for severe forms.
Description: Value of 6 or greeter on WHO CoVid-19 scale, indicating of a critical form of CoVid-19.
Measure: Percentage of patients who reached, during their hospitalization, a value greater than or equal to 6 on the WHO CoVid-19 infection progression scale Time: up to 28 days (during hospitalisation)Description: Radiological damage (extension of ground-glass) could be a predictive factor.
Measure: Determined potential predictive factors of critic form in patients with chronic lung diseases Time: up to 28 days (during hospitalisation)Description: intra-hospital death, intra-ICU death
Measure: Determined percentage of death Time: up to 28 days (during hospitalisation)Description: in days (or duration at a different flow rate compared to long-term home oxygen therapy prior to hospitalization)
Measure: Determined duration of oxygen therapy Time: up to 28 days (during hospitalisation)Description: in days for patients with chronic respiratory disease between the date of admission and the date of discharge. Patients who died during hospitalization will be assigned the highest cohort value.
Measure: Determined duration of hospitalization Time: up to 28 days (during hospitalisation)Description: values will be measured at D3, D7 and D14 in each of the groups. Patients who do not reach D7 and D14 will have the last postponement
Measure: Determine mean values of the WHO CoVid-19 infection progression scale measured Time: up to 28 days (during hospitalisation)This study aim is to assess impact of COVID-19 infection during pregnancy on outcome of pregnancy, and on developement of the child in early life.
Description: Incidence of miscarriage, premature delivery, low birth weight, preeclampsia, chorioamnionitis
Measure: Outcome of pregnancy Time: Up to the deliveryDescription: Measure of antibodies in maternal serum at delivery
Measure: Prevalence of positive serology to SARS-CoV-2 at delivery Time: At the deliveryDescription: Measure the ratio of cord blood antibodies on maternal antibodies titers
Measure: Transplacental transfer of antibodies to SARS-CoV-2 Time: At the deliveryDescription: Placental histology will be performed in women tested positive for SARS-CoV-2 during pregnancy
Measure: To characterize placental alterations related to SARS-CoV-2 infection Time: At the deliveryDescription: Measure of antibodies in cord blood and at the age of 1 month
Measure: To characterize the immunity transmitted to the newborn to cord blood and its persistence at the age of 1 month of life Time: Up to 1 month post deliveryDescription: Occurence of infectious disease, neurological development, growth
Measure: Clinical evolution of the children Time: Up to 3 years